[1-[[1-[[4-(3-Hydroxytetradecanoylamino)-5-phosphonooxypentyl]amino]-1-oxo-4-phosphonooxybutan-2-yl]amino]-1-oxotetradecan-3-yl] dodecanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [1-[[1-[[4-(3-Hydroxytetradecanoylamino)-5-phosphonooxypentyl]amino]-1-oxo-4-phosphonooxybutan-2-yl]amino]-1-oxotetradecan-3-yl] dodecanoate
• 化学式: C₄₉H₉₇N₃O₁₄P₂
• 分子量: 1014.3
• InChiKey: RRDJTUCTAYHWPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.3
• 重原子数：
  68
• 可旋转键数：
  50
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  267
• 氢给体数：
  8
• 氢受体数：
  14

文献信息

• Novel acyl-dipeptide-like compounds, a method for preparing the same and pharmaceutical compositions containing such products
  申请人：Bauer Jacques

  公开号：US20060148678A1

  公开（公告）日：2006-07-06

  The invention relates to the field of chemistry and more specifically to the field of medicinal chemistry. The invention is directed to N-acyl-dipeptide-like compounds having the general formula I wherein substituents A, B, X, Y, R 1 , R 2 , and subscripts n, m, p and q have the same meanings as those given in the claims. The invention is equally directed to pharmaceutical compositions containing as an active ingredient at least one compound of general formula I either in acid or salt form with an organic or mineral base. The compounds persuant to the invention display interesting pharmacological properties which make them useful as drugs.

  这项发明涉及化学领域，更具体地涉及药物化学领域。该发明涉及具有通式I的N-酰基二肽类化合物，其中取代基A、B、X、Y、R1、R2以及下标n、m、p和q的含义与索赔中给出的相同。该发明还涉及含有作为活性成分的至少一种通式I化合物的药物组合物，其以有机或矿物质碱的酸或盐形式存在。根据该发明的化合物展示出有趣的药理特性，使它们可用作药物。
• REDUCING INTERFERENCE BETWEEN OIL-CONTAINING ADJUVANTS AND SURFACTANT-CONTAINING ANTIGENS
  申请人：Novartis Vaccines and Diagnostics S.r.l.

  公开号：EP1909830B1

  公开（公告）日：2011-09-28
• Reducing interference between oil-containing adjuvants and surfactant-containing antigens
  申请人：Contorni Mario

  公开号：US20090220547A1

  公开（公告）日：2009-09-03

  Inclusion of fatty adjuvants in vaccine compositions can cause difficulties with certain antigenic components, particularly with antigens that include a surfactant component. A method for preparing an immunogenic composition comprising an antigen and a fatty adjuvant involves purification of the antigen substantially in the absence of surfactant. Where surfactants cannot be avoided, the following are combined: (i) an antigen component that includes a surfactant and (ii) a fatty adjuvant component, to give a composition in which the weight ratio of said fatty adjuvant to said surfactant is less than 1000:1.
• US7157092B1
  申请人：——

  公开号：US7157092B1

  公开（公告）日：2007-01-02
• [EN] REDUCING INTERFERENCE BETWEEN OIL-CONTAINING ADJUVANTS AND SURFACTANT-CONTAINING ANTIGENS<br/>[FR] REDUCTION DES INTERACTIONS ENTRE ADJUVANTS HUILEUX ET ANTIGENES TENSIOACTIFS
  申请人：NOVARTIS VACCINES & DIAGNOSTIC

  公开号：WO2007015167A2

  公开（公告）日：2007-02-08

  [EN] Inclusion of fatty adjuvants in vaccine compositions can cause difficulties with certain antigenic components, particularly with antigens that include a surfactant component. A method for preparing an immunogenic composition comprising an antigen and a fatty adjuvant involves purification of the antigen substantially in the absence of surfactant. Where surfactants cannot be avoided, the following are combined: (i) an antigen component that includes a surfactant and (ii) a fatty adjuvant component, to give a composition in which the weight ratio of said fatty adjuvant to said surfactant is less than 1000:1.
  [FR] L'inclusion d'adjuvants huileux dans des compositions vaccinales peut ne pas convenir à certains composants antigènes, notamment pour des antigènes comprenant un composant tensioactifs. L'invention propose donc un procédé permettant l'élaboration d'une composition immunogène comprenant un antigène et un adjuvant gras avec purification de l'antigène sensiblement en l'absence de tout tensioactif. Lorsque le recours aux tensioactifs est inévitable, on combine (i) un composant antigène incluant un tensioactif et (ii) un adjuvant gras de façon à obtenir une composition dans le rapport massique entre l'adjuvant gras et le tensioactif est inférieur à 1000:1.